{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:49:26Z","timestamp":1790426966895,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1053\/j.gastro.2017.12.015","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T20:39:40Z","timestamp":1513888780000},"page":"1435-1448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1\u20137 and Escape Variants"],"prefix":"10.1053","volume":"154","author":[{"given":"Judith M.","family":"Gottwein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long V.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte S.","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santseharay","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troels K.H.","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.R.","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2017.12.015_bib1","unstructured":"American Association for the Study of Liver Diseases HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http:\/\/www.hcvguidelines.org. Accessed November 1, 2017."},{"key":"10.1053\/j.gastro.2017.12.015_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","volume":"66","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.12.015_bib3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17474124.2017.1351295","article-title":"Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C","volume":"11","author":"Voaklander","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2017.12.015_bib4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-017-0817-y","article-title":"Glecaprevir\/pibrentasvir: first global approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"10.1053\/j.gastro.2017.12.015_bib5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"10.1053\/j.gastro.2017.12.015_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0065-3527(08)00002-X","article-title":"Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems","volume":"71","author":"Gottwein","year":"2008","journal-title":"Adv Virus Res"},{"key":"10.1053\/j.gastro.2017.12.015_bib7","doi-asserted-by":"crossref","first-page":"e1002696","DOI":"10.1371\/journal.ppat.1002696","article-title":"Analysis of functional differences between hepatitis C virus NS5A of genotypes 1\u20137 in infectious cell culture systems","volume":"8","author":"Scheel","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1053\/j.gastro.2017.12.015_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.12.015_bib9","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.12.015_bib10","first-page":"2","volume":"98","author":"Simmonds","year":"2017","journal-title":"ICTV virus taxonomy profile: Flaviviridae. J Gen Virol"},{"key":"10.1053\/j.gastro.2017.12.015_bib11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jvh.12635","article-title":"Pan-genotypic treatment regimens for hepatitis C virus: advantages and disadvantages in high- and low-income regions","volume":"24","author":"Hezode","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2017.12.015_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.12.015_bib13","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/gutjnl-2015-310421","article-title":"Hepatitis C virus treatment in the real world: optimising treatment and access to therapies","volume":"64","author":"Zoulim","year":"2015","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2017.12.015_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.12.015_bib15","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/cid\/ciw554","article-title":"Transmission of HCV NS5A inhibitor-resistant variants among HIV-infected men who have sex with men","volume":"63","author":"Abravanel","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2017.12.015_bib16","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.12.015_bib17","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in\u00a0vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib18","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in\u00a0vitro and in\u00a0vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.12.015_bib19","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","article-title":"Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2017.12.015_bib21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In\u00a0vitro and in\u00a0vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib22","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.02524-15","article-title":"In\u00a0vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir","volume":"60","author":"Cheng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib23","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.06169-11","article-title":"In\u00a0vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/infdis\/jiv379","article-title":"NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection","volume":"213","author":"Zhou","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2017.12.015_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J\u00a0Clin Virol"},{"key":"10.1053\/j.gastro.2017.12.015_bib26","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib27","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1128\/JVI.00253-11","article-title":"Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052","volume":"85","author":"Fridell","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2017.12.015_bib28","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","article-title":"Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors","volume":"147","author":"McGivern","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.12.015_bib30","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1128\/AAC.01256-12","article-title":"Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells","volume":"56","author":"Saeed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrgastro.2016.37","article-title":"Experimental models of hepatitis B and C\u2014new insights and progress","volume":"13","author":"Thomas","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2017.12.015_bib32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1053\/j.gastro.2010.11.036","article-title":"Recombinant HCV variants with NS5A from genotypes 1\u20137 have different sensitivities to an NS5A inhibitor but not interferon-alpha","volume":"140","author":"Scheel","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.12.015_bib33","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1128\/AAC.02164-12","article-title":"Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses","volume":"57","author":"Gottwein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib34","first-page":"E1101","article-title":"Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2017.12.015_bib35","doi-asserted-by":"crossref","first-page":"19757","DOI":"10.1073\/pnas.1218260109","article-title":"Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2017.12.015_bib36","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2013.11.009","article-title":"Differential sensitivity of 5\u2032UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors","volume":"146","author":"Li","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.12.015_bib37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.26660","article-title":"Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors","volume":"59","author":"Ramirez","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.12.015_bib38","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","article-title":"Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir","volume":"151","author":"Ramirez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.12.015_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00037-17","article-title":"Efficient hepatitis C virus genotype 1b core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors","volume":"61","author":"Pham","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"10.1053\/j.gastro.2017.12.015_bib41","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/hep.21377","article-title":"A\u00a0comprehensive system for consistent numbering of HCV sequences, proteins and epitopes","volume":"44","author":"Kuiken","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2017.12.015_bib42","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1128\/JVI.01605-10","article-title":"Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations","volume":"85","author":"Scheel","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2017.12.015_bib43","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1053\/j.gastro.2007.08.005","article-title":"Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a\/2a (S52\/JFH1) viruses","volume":"133","author":"Gottwein","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.12.015_bib44","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1128\/JVI.00049-11","article-title":"Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A","volume":"85","author":"Gottwein","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2017.12.015_bib45","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/JVI.02667-09","article-title":"Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and\u00a0in\u00a0vivo pathogenesis studies","volume":"84","author":"Gottwein","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1053\/j.gastro.2017.12.015_bib46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.gastro.2011.06.004","article-title":"Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3\/4A protease recombinant viruses","volume":"141","author":"Gottwein","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2017.12.015_bib47","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/651579","article-title":"Challenge pools of hepatitis C virus genotypes 1\u20136 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models","volume":"201","author":"Bukh","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2017.12.015_bib48","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/JCM.02831-14","article-title":"Hepatitis C virus genotype 7, a new genotype originating from central Africa","volume":"53","author":"Murphy","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1053\/j.gastro.2017.12.015_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2016.02.042","article-title":"Sofosbuvir\/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial","volume":"65","author":"Younossi","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2017.12.015_bib50","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1128\/AAC.01953-15","article-title":"Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance","volume":"59","author":"Jensen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib51","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.02929-15","article-title":"Hepatitis C virus genotype 1 to 6 protease inhibitor escape variants: in\u00a0vitro selection, fitness, and resistance patterns in the context of the infectious viral life cycle","volume":"60","author":"Serre","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2017.12.015_bib52","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508517367203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508517367203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:42:59Z","timestamp":1762162979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508517367203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0016508517367203"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2017.12.015","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1\u20137 and Escape Variants","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2017.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the AGA Institute","name":"copyright","label":"Copyright"}]}}